Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

IFL protocol × Tumor-Agnostic × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 27 Thoracic 3 Genitourinary 3 Other solid neoplasm 2 Head & Neck 2 Gynecologic 2 Dermatologic 2 Tumor-Agnostic 1 Sarcoma 1 Other hematologic neoplasm 1 Lymphoid 1 Endocrine 1 CNS 1 Breast 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 52 Specimen Handling 29 Magnetic Resonance Spectroscopy 26 Biopsy 23 Nivolumab 20 Paclitaxel 19 Standard of Care 18 Blood Specimen Collection 17 atezolizumab 15 Bevacizumab 15 Surveys and Questionnaires 12 Fluorouracil 12 Cyclophosphamide 12 Carboplatin 12 Oxaliplatin 11 Radiotherapy 10 Leucovorin 10 Cisplatin 10 olaparib 9 Radiosurgery 9 Irinotecan 9 Ipilimumab 9 Interviews as Topic 9 Capecitabine 9 trastuzumab deruxtecan 8 Gemcitabine 8 Docetaxel 8 durvalumab 7 avelumab 7 Taxes 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03806309 2025-07-25

TEDOPAM

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Active not recruiting

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡